Roivant Sets Stage For Phase 2 PHocus Readout Of Mosliciguat In PH-Interstitial Lung Disease

Roivant (ROIV), a commercial-stage biopharmaceutical company, and its subsidiary, Pulmovant, announced that results from the Phase 2 PHocus study of Mosliciguat in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) will be presented at the European Respiratory Society (ERS) International Congress 2026 on Tuesday, September 8, 2026.